UBS Group AG Increases Stock Holdings in Protara Therapeutics, Inc. $TARA

UBS Group AG raised its stake in Protara Therapeutics, Inc. (NASDAQ:TARA) by 44.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,215,537 shares of the company’s stock after purchasing an additional 372,463 shares during the period. UBS Group AG’s holdings in Protara Therapeutics were worth $6,479,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Millennium Management LLC increased its stake in Protara Therapeutics by 22.0% in the third quarter. Millennium Management LLC now owns 688,256 shares of the company’s stock valued at $2,994,000 after purchasing an additional 124,136 shares during the last quarter. Geode Capital Management LLC increased its stake in Protara Therapeutics by 114.7% in the second quarter. Geode Capital Management LLC now owns 744,519 shares of the company’s stock valued at $2,256,000 after purchasing an additional 397,822 shares during the last quarter. Adage Capital Partners GP L.L.C. purchased a new position in Protara Therapeutics in the second quarter valued at approximately $1,212,000. Marshall Wace LLP purchased a new position in Protara Therapeutics in the second quarter valued at approximately $1,098,000. Finally, American Century Companies Inc. increased its stake in Protara Therapeutics by 69.8% in the second quarter. American Century Companies Inc. now owns 61,554 shares of the company’s stock valued at $187,000 after purchasing an additional 25,305 shares during the last quarter. 38.13% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Protara Therapeutics news, insider Jacqueline Zummo sold 22,598 shares of the firm’s stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $5.26, for a total value of $118,865.48. Following the completion of the sale, the insider owned 95,961 shares of the company’s stock, valued at approximately $504,754.86. This trade represents a 19.06% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 7.60% of the company’s stock.

Protara Therapeutics Price Performance

Shares of NASDAQ TARA opened at $4.34 on Wednesday. The stock has a fifty day moving average price of $5.21 and a 200 day moving average price of $5.69. Protara Therapeutics, Inc. has a 1-year low of $2.77 and a 1-year high of $7.82. The company has a market cap of $243.91 million, a PE ratio of -3.24 and a beta of 1.53.

Protara Therapeutics (NASDAQ:TARA) last released its earnings results on Wednesday, May 13th. The company reported ($0.31) EPS for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.05. Analysts anticipate that Protara Therapeutics, Inc. will post -1.42 earnings per share for the current fiscal year.

More Protara Therapeutics News

Here are the key news stories impacting Protara Therapeutics this week:

• Positive Sentiment: Protara said its mid-stage non-muscle invasive bladder cancer study showed durable treatment activity for TARA-002, which supports the drug’s clinical promise and may strengthen confidence in the program. Protara’s cell therapy shows treatment durability in mid-stage NMIBC study
• Positive Sentiment: HC Wainwright raised earnings estimates across several future years and maintained a Buy rating with a $27 price target, signaling confidence in Protara’s longer-term outlook.
• Positive Sentiment: Protara is also hosting a virtual investor webinar on TARA-002 and lymphatic malformations, which could help explain the opportunity around the program and keep the stock in focus. Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026
• Neutral Sentiment: The webinar and related materials reinforce that TARA-002 remains an investigational therapy in ongoing trials for both bladder cancer and rare pediatric lymphatic malformations, so execution and regulatory risk remain important.

Wall Street Analyst Weigh In

TARA has been the topic of a number of research reports. JPMorgan Chase & Co. lowered their target price on shares of Protara Therapeutics from $27.00 to $26.00 and set an “overweight” rating on the stock in a research report on Thursday, May 14th. Wall Street Zen upgraded shares of Protara Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday. Weiss Ratings restated a “sell (d-)” rating on shares of Protara Therapeutics in a research report on Tuesday, April 21st. TD Cowen restated a “buy” rating on shares of Protara Therapeutics in a research report on Tuesday, March 10th. Finally, HC Wainwright raised their target price on shares of Protara Therapeutics from $23.00 to $27.00 and gave the stock a “buy” rating in a research report on Wednesday, April 29th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $24.50.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company’s primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body’s immune response to target tumor cells. Protara’s therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara’s lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.